Skip to main content

Table 3 Mean change in 7-day average WOMAC A1 from baseline over 26 weeks

From: Efficacy and safety of a single intra-articular injection of 6 ml Hylan G-F 20 compared to placebo in Chinese patients with symptomatic knee osteoarthritis

  Placebo (N = 220) Single 6 ml Hylan G-F 20 injection (N = 218)
Baseline
 Number 220 216
 Mean (SD) 5.34 (1.03) 5.48 (1.07)
 Median 5.14 5.36
 Min; Max 3.7; 8.0 3.7; 8.3
Change from baseline over 26 weeks
 LS Mean (SE) −2.275 (0.108) −2.176 (0.106)
 LS Mean Difference (SE) vs. Placebo   0.099 (0.135)
 95% CI   (−0.166 to 0.364)
P-value   0.4637
  1. Least-square (LS) means, standard errors (SE) and p-value are taken from repeated measures of Covariance analysis. The model includes treatment groups (Single 6 ml Hylan G-F 20 injection and placebo), site, visit and visit by treatment interaction, as well as the baseline 7-day average WOMAC A1 score as a covariate. Included are patients who have measurements at baseline and at least one post-baseline value